130466-73-8

Basic information

• Product Name: tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate
• Synonyms: tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate
• CAS NO: 130466-73-8
• Molecular Weight: 499.653
• Mol File: 130466-73-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate(130466-73-8)
• EPA Substance Registry System: tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate(130466-73-8)

Safety Data

• Hazardous Substances Data: 130466-73-8(Hazardous Substances Data)

Upstream product

• 700-57-2 1-adamantanol 
• 150871-31-1 N-<(2-adamantyloxy)carbonyl>-DL-α-methyltryptophan methyl ester 
• 130406-42-7 2-[(Adamantan-2-yl-oxy)-carbonyl]-amino-3-(1H-indol-3-yl)-2RS-methyl-propionic acid 
• 64-04-0 phenethylamine 
• 114779-47-4 (2-phenylethyl)amine 
• 53120-53-9 2-adamantyl chloroformate 

Relevant articles and documents

CHOLECYSTOKININ ANTAGONISTS USEFUL IN THE TREATMENT OF PANIC ATTACKS

Unnatural dipeptoids of α-substituted Try-Phe derivatives are useful as agents in the treatment of panic disorders. These dipeptoids are Cholecystokinin-B Receptor (CCK B) antagonists having utility in the prevention of panic attacks in patients prone to these attacks.

Rationally designed 'dipeptoid' analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyl-tryptophan derivatives

The structure-affinity relationships (SAR) between the N-terminii of a series of α-methyl-tryptophanylphenethylamide derivatives and the cholecystokinin (CCK) B receptor are discussed. A series of compounds with the general formula R-X-α-methyl-tryptophanylphenethylamide was prepared, where R is a cycloalkyl, a bicycloalkyl or a tricycloalkyl group and X is a urethane, thiourethane, amide, urea or a sulphinamide linking group. The CCK-B receptor binding affinities of these are discussed. The SAR form part of a systematic program for the rational design of 'dipeptoid' analogues of the neuropeptide CCK. Beginning with 1,1-dimethylpropyl (±)-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2- [(2-phenylethyl)amino carbamate (IC50 = 4720 nM on CCK-B binding affinity) the N-terminal moiety was systematically changed for groups of varying size, shape and lipophilicity until the optimal N-terminal group was obtained and the favoured linking group chosen, resulting in the compound tricyclo[3.3.1.13,7)]dec-2-yl(R)-[(1H-indol-3-ylmethyl)-1-methyl- 2-oxo-2[(2-phenylethyl)amino]ethyl]carbamate with and IC50 = 32 nM on CCK-B receptor binding affinity.

Rationally Designed "Dipeptoid" Analogues of CCK. α-Methyltryptophan Derivatives as Highly Selective and Orally Active Gastrin and CCK-B Antagonists with Potent Anxiolytic Properties

This paper describes the synthesis and structure-activity relationships (SAR) leading to the first rational design of "dipeptoid" analogues of the neuropeptide cholecystokinin (CCK).Compounds *,S*)>-4-2-3-(1H-indol-3-yl)-2-m